New combo pill for diabetes tested in thousands of patients
NCT ID NCT07023172
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is tracking 3000 adults with type 2 diabetes who are starting a new combination pill called Proline Plus Empagliflozin. Researchers want to see how well it controls blood sugar and if it is safe when used in everyday medical practice. The study does not change how doctors treat patients—it simply observes what happens over 24 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Proline Plus Empagliflozin tablets (a combination drug to lower blood sugar)
What this could lead to
If successful, this study could confirm that Proline Plus Empagliflozin works well in everyday practice for managing type 2 diabetes.
What could go wrong
This is an observational study, not a controlled trial, so results may be less reliable. It is also only for people already prescribed the drug, limiting generalizability.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Affiliated Drum Tower Hospital, Medical School of Nanjing University
RECRUITINGNanjing, Jiangsu, 210000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Xinyang Central Hospital
RECRUITINGXinyang, Henan, 464000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••